Evid Based Complement Alternat Med , 2015:2015:713218
Taking semaglutide and tirzepatide as two distinct weekly injections is technically possible but clinically inefficient because tirzepatide already includes GLP-1 receptor agonism
We did not identify any difference in data distribution, so no further adjustment was done
Most regulated private prescribers and clinics will only prescribe GLP-1 from a BMI of 30 or above, or a BMI of 27 or above where there is a significant weight-related health condition present
A list of known possible side effects will always be available in the patient information leaflet
In other words, you would receive one month (4 injections) of 0.25 mg, one month (4 injections) of 0.5 mg, and so forth to 1.0 mg, 1.7 mg, and finally 2.4 mg, assuming your side effects are minimal